What Stage Is Well-Differentiated Squamous Cell Carcinoma?

Well-differentiated is a grade, not a stage, and the distinction matters more than most patients realize. A squamous cell carcinoma (SCC) that a pathologist calls “well-differentiated” can show up at Stage I, Stage II, Stage III, or even Stage IV depending on the tumor’s size, depth, location, and whether it has spread to lymph nodes or distant organs. Grade describes how the cancer cells look under a microscope, while stage describes how far the cancer has physically traveled. The two systems measure different things, and confusing them can lead to real misunderstandings about what a diagnosis means.

What “Well-Differentiated” Actually Tells You

When a pathologist examines a biopsy, one of the things they report is how closely the cancer cells resemble normal tissue. A well-differentiated squamous cell carcinoma still looks a lot like normal squamous cells. The cells are organized, they produce keratin in recognizable patterns, and the tissue architecture hasn’t completely broken down. By contrast, a poorly differentiated tumor looks chaotic under the microscope: the cells have lost most of their resemblance to normal tissue, they divide more aggressively, and they tend to invade surrounding structures more readily.

Most grading systems divide SCC into three tiers: well-differentiated (Grade 1), moderately differentiated (Grade 2), and poorly differentiated (Grade 3). Some older classification schemes, like the one Broders originally proposed, use four tiers instead of three. Regardless of the system used, the core idea is the same: higher-grade tumors behave more aggressively on average.

How Staging Works for Squamous Cell Carcinoma

Staging is a separate assessment. It measures the physical extent of the cancer: how large the primary tumor is, whether it has invaded nearby structures, whether lymph nodes are involved, and whether it has spread to distant sites. The most widely used framework is the American Joint Committee on Cancer (AJCC) TNM system, which assigns a T category for the primary tumor, an N category for lymph nodes, and an M category for distant metastasis. These three letters combine into an overall stage, typically I through IV.

For cutaneous (skin) SCC, the AJCC 8th edition defines T categories based on tumor diameter and high-risk features. A T1 tumor is smaller than 2 cm, T2 is 2 cm to just under 4 cm, and T3 is 4 cm or larger, or involves minor bone erosion, perineural invasion, or deep invasion. T4 tumors involve major bone invasion or skull base structures.¹ Notice that none of those T definitions mention differentiation grade. A well-differentiated tumor that happens to be 5 cm across would be classified as T3 just like a poorly differentiated one of the same size.

Staging systems for SCC at other body sites follow the same general logic but use site-specific criteria. Oral cavity SCC, for instance, now incorporates depth of invasion into its T classification, while cervical SCC has its own staging framework that includes lymph node involvement as a distinct substage.² In every case, the stage is determined by measurable physical features of the tumor, not by how the cells look under a microscope.

Why Grade and Stage Often Travel Together

Even though grade and stage are formally independent, they aren’t random with respect to each other. Poorly differentiated tumors are more likely to be diagnosed at advanced stages, and well-differentiated tumors are more likely to be caught early. A large retrospective study of oral cavity SCC found that advanced-stage disease was present in about 24% of well-differentiated (Grade 1) cases, compared with 44% of moderately differentiated and 55% of poorly differentiated cases. Lymph node metastases followed an even steeper gradient: roughly 6% in Grade 1 versus 46% in Grade 3.³

So while a well-differentiated SCC can theoretically appear at any stage, the odds favor it being caught at an earlier stage than a poorly differentiated one. This statistical tendency is part of what makes well-differentiated tumors generally lower-risk, but it is a tendency, not a rule. A well-differentiated tumor on the scalp that a patient ignores for a year can grow large enough and deep enough to land in a high T category.

Differentiation Grade as an Independent Prognostic Factor

Here is where the grade-versus-stage question becomes clinically meaningful: even after you account for stage, differentiation still predicts outcomes. In cutaneous SCC, one study found that five-year metastasis-free survival was 70% for well-differentiated tumors, 51% for moderately differentiated, and just 26% for poorly differentiated, with identical percentages for overall survival.⁴ Poorly differentiated tumors were also nearly three times as likely to recur or cause death compared to well-differentiated ones in another analysis.⁵

A population-based study of oral SCC found that among patients with Stage I or II disease, the adjusted risk of death was about 2.7 times higher if the tumor was poorly differentiated or undifferentiated compared with well-differentiated. In patients over 65, that figure climbed to about 3.0 times higher.⁶ The practical takeaway: two people with the same stage of SCC can have meaningfully different outlooks depending on the tumor’s grade.

The AJCC 8th edition staging system for cutaneous SCC now incorporates poor differentiation as a risk factor that can affect the T category in certain circumstances. One study comparing staging editions confirmed that poor differentiation was independently associated with worse outcomes.⁷ Still, in most body sites, differentiation grade is not formally built into the stage designation itself. Oral cavity SCC staging, for instance, does not include cell differentiation as a criterion for determining TNM stage, even though poorly differentiated tumors are associated with recurrence and reduced survival.⁸

Grade Matters Differently at Different Body Sites

SCC arises in squamous cells, which line the skin, mouth, throat, esophagus, lungs, and cervix. The significance of being “well-differentiated” varies depending on where the tumor forms.

For cutaneous SCC, well-differentiated tumors make up the majority of cases and generally carry an excellent prognosis when caught early. Most are small, slow-growing, and cured with straightforward excision. Non-well-differentiated skin tumors, by comparison, tend to be larger, deeper, and more likely to recur.⁹

In the esophagus, differentiation grade has been identified as an independent prognostic factor for survival after surgery, alongside tumor size, cancer stage, and lymph node involvement.¹⁰ Machine-learning models for esophageal SCC prognosis have similarly confirmed that poorly differentiated tumors carry higher mortality risk.¹¹

In the lung, squamous cell carcinoma that is well-differentiated and caught at Stage I is generally the most favorable scenario. But screening data shows that well-differentiated Stage I lung SCC tumors are less commonly detected by low-dose CT compared with lung adenocarcinoma, partly because squamous cell tumors in the lung tend to grow in central airways where they can be harder to spot early.¹²

When Well-Differentiated Tumors Still Behave Aggressively

The assumption that well-differentiated equals low-risk trips people up in certain situations. Immune status is the big one. In organ transplant recipients and others on long-term immunosuppressive therapy, even well-differentiated cutaneous SCC can grow rapidly and behave unpredictably. A recent case report documented a well-differentiated scalp SCC that progressed aggressively in an immunosuppressed patient, underscoring that differentiation grade alone does not guarantee a benign course.¹³

Tumor location also plays a role independent of grade. A well-differentiated SCC on the ear, lip, or temple may carry more risk than one on the trunk simply because of proximity to nerves, cartilage, and lymphatic drainage pathways. The AJCC staging system captures some of this through its T-category definitions (perineural invasion, bone erosion), but not all of it. A tumor in a high-risk location may warrant more aggressive treatment even if it looks reassuringly normal under the microscope.

Size and depth of invasion can override the comfort of a well-differentiated diagnosis. A deep tumor with clear margins of invasion into subcutaneous fat, even if it retains well-organized cell architecture, is not the same clinical problem as a superficial one. The 8th edition of the AJCC system improved its ability to capture these high-risk features: the T3/T4 categories accounted for about 18% of total cases but roughly 70% of disease-related outcomes like local recurrence, nodal metastasis, and disease-specific death.¹⁴

HPV Status Complicates the Picture for Head and Neck SCC

In the head and neck, particularly in the oropharynx (the part of the throat behind the mouth), human papillomavirus (HPV) has introduced an entirely different dimension to staging and prognosis. HPV-positive oropharyngeal SCC behaves so differently from HPV-negative disease that the AJCC 8th edition created a separate staging system for it.¹⁵ Under this separate system, HPV-positive tumors are staged more favorably: what would be Stage IV in the conventional system may be reclassified as Stage I or II if the tumor is HPV-driven, because these tumors respond much better to treatment.

HPV positivity can effectively override traditional prognostic indicators like tumor grade and histological subtype. In the HPV-specific staging system, Stage IV is reserved only for distant metastasis.¹⁶ This is a stark departure from how staging works in other SCC sites and is a good example of how context reshapes the meaning of both grade and stage.

What Drives Squamous Cell Carcinoma in the First Place

Most cutaneous SCC traces back to chronic ultraviolet radiation damage. An early and common step in this process is mutation of the TP53 gene, which normally acts as a brake on uncontrolled cell growth. When TP53 is knocked out by UV-induced DNA damage, additional cancer-promoting mutations accumulate more easily.¹⁷ Research has found TP53 mutations in over half of invasive skin SCCs, with a telltale UV-signature pattern in the mutations themselves.¹⁸

Well-differentiated tumors likely represent an earlier or less disrupted point along this mutational cascade. The cells have acquired enough mutations to grow abnormally but not so many that they lose all semblance of normal tissue organization. Poorly differentiated tumors, by contrast, have typically accumulated more genetic chaos, which is why they tend to be more aggressive. But “well-differentiated” does not mean “few mutations” in any absolute sense; even an orderly-looking tumor can harbor a substantial mutational burden.

Treatment Varies More by Stage Than by Grade

For most patients with cutaneous SCC, treatment is surgical. Standard excision with clear margins cures the vast majority of well-differentiated, early-stage tumors. In cases where the tumor is on the face or in a cosmetically or functionally sensitive area, Mohs micrographic surgery offers the highest cure rates. A ten-year Australian study reported a 2.6% five-year recurrence rate for primary SCCs treated with Mohs surgery, and 5.9% for previously recurrent tumors.¹⁹

When SCC is advanced, either locally advanced (meaning it has invaded deeply or is unresectable) or metastatic, immunotherapy has become an important option. Cemiplimab, a checkpoint inhibitor, is approved for advanced cutaneous SCC that cannot be adequately treated with surgery or radiation.²⁰ This represents a major shift in the management of high-stage disease, particularly for tumors that have spread beyond what a surgeon can remove.

Grade influences treatment decisions mostly at the margins. A well-differentiated Stage I tumor on the trunk might be treated with a simple excision and relatively narrow margins. A poorly differentiated Stage I tumor in the same location might prompt wider margins, consideration of Mohs surgery, or closer follow-up surveillance. The stage is the primary driver of treatment intensity, but grade adjusts it.

The Limits of Grading Systems

Grading tumor differentiation involves a pathologist looking at tissue slides and making a judgment call. Different pathologists can grade the same tumor differently, and the boundaries between “well” and “moderately” differentiated are not always crisp. Some tumors show mixed differentiation, with well-differentiated areas in one section and poorly differentiated areas in another. In these cases, the tumor is typically classified by its worst area, which can mean two biopsies from the same tumor yield different grades if they happen to sample different regions.

Depth of invasion has emerged as a particularly strong predictor of outcomes in oral cavity SCC, in some analyses outperforming traditional grading. This is part of why the current AJCC staging system for oral cancers now incorporates depth of invasion directly into the T classification. The shift reflects a broader trend in oncology: measurable physical characteristics of a tumor, like how deep it has grown, tend to be more reproducible and prognostically reliable than the somewhat subjective assessment of how “differentiated” the cells look.

For esophageal SCC, histologic grade remains a recognized independent prognostic factor alongside T stage, N stage, and resection margin status.²¹ But in lung SCC, one study found that the grade of differentiation was not associated with the expression of certain growth factor receptors, suggesting that the relationship between how a tumor looks and how it behaves at the molecular level is not always straightforward.²² Grading tells you something real, but it does not tell you everything.

Diagnostic Tools Beyond the Biopsy

A biopsy and pathological examination remain the foundation for both grading and staging SCC. The pathologist assesses differentiation, depth of invasion, perineural invasion, lymphovascular invasion, and margin status. For head and neck tumors where the diagnosis is ambiguous, immunohistochemical staining with markers like p40 and p63 can help confirm squamous differentiation, particularly in unusual variants like sarcomatoid carcinoma where the tumor barely resembles squamous tissue at all.²³

Imaging studies like CT, MRI, and PET scans play a role in staging rather than grading. They help determine whether the tumor has invaded bone, spread to lymph nodes, or metastasized to distant organs. For cervical SCC, imaging and pathological findings are now both formally integrated into the staging system.² For skin SCC, imaging is generally reserved for high-risk tumors or cases where deeper invasion is suspected, since the vast majority of cutaneous SCCs are diagnosed and staged entirely by clinical examination and biopsy findings.